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A new class of murine leukemia viruses (MuLV) 1 has been designated as mink cell 
focus-inducing (MCF) for their ability to induce cytopathie foci when grown on mink 
lung fibroblasts (1). The classic MCF virus is an XC-negative, dual-tropic virus that 
appears  to  be  an  envelope gene  recombinant  between  ecotropic and  endogenous 
xenotropic viral sequences (2-7). An association between a variety of leukemias and 
MCF viruses is becoming increasingly apparent. Hartley et al. (1) first demonstrated 
that MCF viruses could be isolated from thymic lymphomas of AKR mice, and it was 
subsequently shown (8) that such viruses can accelerate leukemia in the AKR mouse. 
MCF  viruses  have  also  been  implicated  in  diseases  induced  by  Moloney  (9)  and 
Rauscher  (10)  MuLV and in x ray-induced lymphomas (11), graft vs. host-induced 
reticulum cell neoplasms (12), and plasmacytomas (13). 
Helper-independent virus from a molecularly cloned stock of NB-ecotropic Friend 
MuLV (F-MuLV) induces in newborn NIH Swiss and BALB/c mice an erythropro- 
liferative  disease  characterized  by  splenomegaly  and  severe  anemia  (14-16).  As 
demonstrated by molecular hybridization techniques, spleens from F-MuLV-infected 
mice, as compared with spleens from uninfected mice, express 100 to 1,000-fold higher 
levels of xenotropic virus-related RNA sequences, and subsequently MCF viruses were 
isolated from several of these spleens (14). 
In an effort to better understand F-MuLV-induced disease in the mouse and the 
role  that  MCF  viruses  play  in  this  disease,  a  series  of studies  was  carried  out  to 
determine the susceptibility of various strains of mice to disease induced by F-MuLV, 
to characterize the viruses and viral proteins expressed in the spleens of infected and 
uninfected mice, and to determine whether Friend MCF virus (Fr-MCF) induces the 
same disease. We report that the erythroproliferative disease developing in susceptible 
F-MuLV-infected mice  is  correlated with  the  expression of MCF-related  envelope 
glycoproteins and that MCF viruses isolated from these mice are moderately patho- 
genic when infected as pseudotypes prepared by mixed infection with either ecotropic 
1 Abbreviations used in this paper: Amph 4070, amphotropic virus 4070; F or Fr, Friend; FFU, focus-forming 
units;  HaSV, Harvey sarcoma virus; MCF, mink cell focus-inducing  virus; MuLV, murine leukemia virus; 
PFU, plaque-forming units; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis;  SFFV, 
Friend strain of spleen focus-forming  virus. 
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or amphotropic MuLV. We also report the expression of an MCF/xenotropic virus- 
related envelope protein in cells from uninfected, resistant but not susceptible strains 
of mice, which may represent the basis for resistance to F-MuLV-induced disease. 
Materials and Methods 
Cell Lines and Viruses.  The F-MuLV used in these studies was the molecularly cloned stock 
of F-MuLV clone 201 that has been previously described (16). Amphotropic virus 4070 (Amph 
4070),  obtained from Dr. Janet Hartley, National Cancer Institute, Bethesda, Md., has also 
been previously described (17). 
Cell-free homogenates (10% wt/vol) of splenic tissue were prepared by douncing spleens in 
Dulbecco-Vogt medium containing 10% calf serum and clarifying by centrifugation at 2,000 
rpm for  10 min. NIH 3T3 cells were then infected with various dilutions of each homogenate, 
and  supernates  of  the  infected  cells  were  monitored  for  virus  production  by  the  reverse 
transcriptase assay (18, 19). 
Fr-MCF-1 virus, obtained from the spleen of an NIH Swiss mouse infected as a  newborn 
with F-MuLV clone 201, has been previously described (20). NIH 3T3 cells were infected with 
this virus, and F-MuLV or Amph 4070 pseudotypes of Fr-MCF were prepared by superinfecting 
Fr-MCF-1-infected  NIH 3T3 cells with one or the other virus. Infection of the Fr-MCF-1/NIH 
3T3 cells with F-MuLV was monitored by the appearance of XC+ virus in the supernate from 
the cells. Infection of the Fr-MCF-infected cells with amphotropic virus was more difficult to 
confirm. Because both Fr-MCF and amphotropic viruses fail to induce XC  plaques under 
standard conditions, we did not use the XC plaque assay to monitor the infection. Instead, we 
assessed the presence of each of these viruses by using the supernate from a culture of Fr-MCF- 
1/NIH 3T3 cells infected with Amph 4070 to rescue replication-defective Harvey sarcoma virus 
(HaSV)  from  NIH  3T3  cells  nonproductively infected with  HaSV.  Supernates  from  the 
superinfected HaSV-NIH 3T3 cell culture were then plated onto NIH 3T3 cells  that were 
themselves singly infected with either Fr-MCF-1 or Amph 4070. Viral interference inhibits the 
infection of each cell line with HaSV pseudotyped with the envelope of the virus already in the 
cells but not with the HaSV pseudotype formed with the other replication-competent  retrovirus. 
Thus, transmission of focus-forming activity to both Fr-MCF-1/NIH 3T3 cells  and Amph 
4070/NIH 3T3 cells confirmed that the original cell culture was producing both Fr-MCF and 
amphotropic viruses. 
3T3 embryo cell lines derived from NIH Swiss, BALB/c, DBA/2, and C57BL/6 mice have 
been previously described (21-23). 
Virus Titration Assays.  Cell-free spleen homogenates prepared from infected mice were titered 
for virus by plating on S+L-  mouse cells  (D56),  which will detect both ecotropic and dual- 
tropic viruses. This assay has been previously described (24). 
Animals and Leukemogenicity assays.  All mice used in these studies were obtained from the 
National Institutes of Health small animal facility. Mice were inoculated intraperitoneally as 
newborns with 0.1  ml of a  1:5 dilution of F-MuLV clone 57 (corresponding to ~1  X  10  s XC 
plaque-forming units  [PFU]  of virus)  and  were  killed at  intervals between  5  and  21  wk 
postinfection. Mice were considered disease  positive if the spleen weight was >0.5 g  (normal 
spleen wt=  ~0.1  g)  and the  hematoerit  was <35%  (normal hematoerit=  ~48%).  Wright- 
Giemsa-stained cytocentrifuge preparations were also prepared to confirm the erythroprolifer- 
ative nature of the disease. 
Sera. Goat anti-Rauscher MuLV gp70 serum, which will detect both ecotropic and MCF 
gp70,  was  obtained from  the  Division of Cancer Cause  and  Prevention, National Cancer 
Institute, Bethesda, Md. An antiserum that specifically precipitates MCF gp70 was obtained 
by absorbing goat  anti-Moloney MCF  gp70  serum with ecotropic  F-MuLV, as  previously 
described (25). 
Pulse-Labeling,  Immune Precipitation, and Polyacrylamide Gel Electrophoresis.  Virus-infected fibro- 
blasts were pulse labeled with [35S]methionine, as previously described (25). Bone marrow cells 
3~  were obtained from the femurs of mice and labeled with [  S]methionine at a concentration of 
1 X  10  7 cells/0.5 mCi of isotope in a 2-ml vol. Extracts of cells were immune precipitated with 
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sulfate-polyacrylamide  gels  (SDS-PAGE),  and the  gels  were  fluorographed  and exposed  to  x- 
ray film, as previously  described  (26). 
Results 
Pathogenicity of F-MuL V in  Various Strains of Mice.  To  determine  the strain  distri- 
bution for pathogenicity, various strains of mice were injected with F-MuLV. Because 
it  has  previously  been  demonstrated  that  newborn  but  not  adult  NIH  Swiss  and 
BALB/c  mice  develop  disease  after injection of F-MuLV,  all mice  were  injected as 
newborns with  1  ×  105 XC-PFU  of virus.  The  results  are  shown  in  Table  I.  NIH 
Swiss,  BALB/c,  and  C3H/He  mice  are  the  most  susceptible  to  F-MuLV-induced 
erythroleukemia, with 75-100% of infected mice developing signs of the disease within 
6  wk.  Approximately  40%  of all  AL,  NZW,  and C58/Lw  mice  inoculated with  F- 
MuLV developed disease within 8 wk. The remaining mice tested, DBA/2,  DBA/1, 
C57BL/6,  C57BL/10,  CBA,  C57L,  and AKR,  showed  no evidence  of disease  by 6 
mo. Infected DBA/2 and C57BL/6 mice have remained disease free for as long as  12 
mo postinjection. Infection of DBA/2 and C57BL/6 mice with fivefold more virus (5 
×  105 XC-PFU)  still had no disease-producing effect when animals were examined as 
late  as  11  mo  postinfection.  F1  hybrids  between  DBA/2  and  either  NIH  Swiss  or 
BALB/c  mice  were  resistant  to  disease,  as were  F1  hybrids between  C57BL/6  and 
either  NIH  Swiss  or  BALB/c  mice,  which  suggests  that  resistance  to  disease  is 
TAaLE  I 
E~ythroproliferative Disease in Various Strains of Mice Inoculated with F-MuL V 
Incidence of 
Strain  disease*  Latency:l:  Fv- 1  Fv-2  H-2 
%  d 
NIH Swiss (NFS)§  100(14/14)  35-49  n  s  q 
BALB/cAnN  75(12/16)  35-70  b  s  d 
C3H/HeN  (MMTV+)  80(15/19)  35-70  n  s  k 
NZW/N  39(5/13)  55-125  --  s  -- 
AL/N  39(9/23)  55-119  b  s  a 
C58/LwN  50(6/12)  75-91  n  r  k 
DBA/2N  0(0/19)  --  n  s  d 
DBA/1JN  0 (0/10)  --  n  s  d 
C57BL/6N  0(0/22)  --  b  r  b 
C57BL/10S  0(0/10)  --  b  r  b 
C57L/N  0(0/10)  --  n  r  q 
CBA/N  0(0/22)  --  n  s  k 
AKR/N  0(0/11)  --  n  s  k 
C57BL/6 ×  DBA/2  0(0/8)  --  nb  s  db 
NFS ×  DBA/2  0(0/10)  --  n  s  qd 
NFS ×  C57BL/6  0(0/13)  --  nb  s  qb 
BALB/c  ×  DBA/2  0(0/33)  --  nb  s  d 
BALB/c X  C57BL/6  0(0/12)  --  b  s  db 
(NFS ×  DBA/2)FI ×  NFS  75(15/20)  41-100  n  s  -- 
* Animals were considered  disease  positive  if the spleen  weight was at  least  0.5  g  and the 
hematocrit was <  35%. 
~: Mice  were killed at intervals  between  5  and  21  wk postinfection.  Latency represents  the 
range between the minimum and the maximum time required for evidence of disease to 
appear. 
§ NFS is an inbred strain derived from the outbred NIH Swiss stock. 910  FRIEND MURINE LEUKEMIA VIRUS-INDUCED LEUKEMIA 
dominant in these crosses.  75% of NFS X  DBA/2 Fa hybrid mice backcrossed to NFS 
mice developed disease within 4 mo postinoculation. Although larger numbers of mice 
must  be  tested,  the  data  are consistent  with  resistance  being controlled  by a  single 
dominant gene. 
As indicated in Table I, susceptibility to F-MuLV-induced disease does not appear 
to be under the control of either  the Fv-1 gene, which controls the replication of F- 
MuLV  (27,  28), the Fv-2 locus, which has previously been shown to control suscep- 
tibility to the spleen focus-forming virus (SFFV)  (29), or a  gene contained within the 
H-2  complex.  Because  resistance  to  F-MuLV  disease  is  dominant  and  appears 
absolute, resistant  mice most likely code for a  positive factor that confers resistance. 
Virus-Replication  in  Various Strains  of Mice  Inoculated with  F-MuL V.  Because  other 
known murine resistance systems block replication of the input virus, it was necessary 
to determine  whether  the resistance  of certain  strains  of mice to F-MuLV could be 
due  to  lack  of replication  of the  virus  in  the  spleens  of these  mice.  Thus,  splenic 
homogenates from both susceptible and resistant mice were analyzed for virus titer by 
plating on S+L-  mouse cells. As shown in Table II, the titer of virus usually varied 
between  1  ×  10  ~ and  1  ×  106  focus-forming units  (FFU)/ml  in  all  strains  studied 
except C57BL/6 mice, where the titer averaged  1 ×  104 FFU/ml. The data shown in 
Table  II represent  spleens  taken  4-8 wk postinoculation,  but  titers  in  resistant  and 
susceptible  strains  did  not  differ  significantly  from each  other  or from the  data  in 
Table  II when  analyzed  1-4 wk postinoculation  (data  not  presented).  Also, spleen 
homogenates  from F-MuLV-infected  DBA/2 and  C57BL/6  mice induced  the same 
disease  after  a  similar  latency  period  in  newborn  NIH  Swiss  and  BALB/c  mice, 
indicating that an infectious dose of virus was present  in the resistant strains and that 
the  virus  was  not  being inactivated  in  these  mice.  Thus,  resistance  is  not  due  to a 
block in the replication of F-MuLV. 
Induction of Disease by Fr-MCF Virus.  MCF  viruses  have been  previously isolated 
from the  spleens  of F-MuLV-infected  NIH  Swiss and  BALB/c mice  (20),  and  it  is 
TABLE II 
Titer of Virus Recovered  from Spleens of F-MuL V-infected Mice 
Strain 
Virus titer 
FFU/ml ×  10  -5  Average 
NIH Swiss  1.5-22.0  7.7 
BALB/cAnN  0.9-40.0  15.5 
AL/N  0.1-4.0  1.3 
NZW/N  4.0-20.0  8.3 
C3H/HeN  3.1-8.6  5.8 
DBA/2N  0.5-7.7  3.2 
C57BL/6N  0.03-0.5  .20 
C57BL/10ScN  1.1-3.5  2.3 
CBA/N  0.05-12.0  2.7 
AKR/N  2.1-2.2  2.1 
C57BL/6 × DBA/2 F1  0.4-18.0  3.2 
BALB/c × DBA/2 FI  0.3-3.0  1.3 
10%  (wt/vol) spleen homogenates were prepared  from spleens of mice and 
titered on S+L- mouse cells, as described in Materials and Methods. Values 
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possible that such viruses play a  role in the induction of disease.  If so, Fr-MCF virus 
should  induce the same disease and  follow the same resistance  pattern  as F-MuLV. 
Thus, Fr-MCF-1  virus isolated from the spleen of a  newborn NIH Swiss mouse given 
F-MuLV was compared with its eeotropie parent,  F-MuLV clone 201, for its ability 
to induce an erythroproliferative  disease  in adult  NIH Swiss mice.  It has previously 
been shown (14,  15,  30) that adult  NIH Swiss mice are relatively resistant  to disease 
induced  by  F-MuLV  alone.  As  shown  in  Table  III,  Fr-MCF  virus  alone  is  not 
pathogenic  in  adult  mice.  However,  the  virus  titer  in  the  spleens  of the  Fr-MCF- 
infected animals was very low (~ 10 x FFU/ml). In an effort to increase the replication 
of Fr-MCF  virus  in  vivo,  an  F-MuLV  pseudotype  of Fr-MCF  was  prepared  and 
injected  into  adult  NIH  Swiss  or DBA/2  mice.  As shown  in Table  III, 60%  of all 
adult  NIH  Swiss  mice  injected  with  the  F-MuLV/Fr-MCF  pseudotype  developed 
disease within 4 mo. The disease was indistinguishable  from that induced in newborn 
NIH Swiss mice by F-MuLV. In contrast, only 13% of aduh NIH Swiss mice injected 
with F-MuLV alone developed disease within 6 mo postinjection.  None of the adult 
DBA/2 mice developed disease after infection with either F-MuLV or the F-MuLV/ 
Fr-MCF  pseudotype.  Newborn  NIH  Swiss  mice  were  also  infected  with  Fr-MCF 
virus.  The  results  were  the  same  as  those  obtained  with  adult  mice:  the  titer  of 
recovered virus was low (~< 101 FFU/ml) and the animals remained healthy. However, 
when newborn NIH Swiss mice were injected with an amphotropic virus pseudotype 
of Fr-MCF,  27% of the mice developed disease within  4  mo.  Neither newborn  NIH 
Swiss mice injected with amphotropic virus alone, nor newborn DBA/2 mice infected 
with the amphotropic virus/Fr-MCF pseudotype, nor amphotropic virus alone showed 
any signs of disease  within  6  mo postinjection.  These results  indicate  that  Fr-MCF 
virus can be pathogenic in both newborn and adult NIH Swiss but not DBA/2 mice 
when  appropriately  pseudotyped,  and  they  suggest  that  Fr-MCF  virus  is  a  likely 
intermediate  in the induction of disease by F-MuLV. 
Infectious  Virus in  Spleens of Susceptible and Resistant Mice  Infected with F-MuL V.  If 
MCF viruses play a  role in the induction of disease  after injection of F-MuLV, one 
might  expect  to  find  evidence  of replication  of such  viruses  in  susceptible  but  not 
resistant  strains of mice.  A  search  for the expression  of MCF viruses is simplified  by 
TABLE III 
Induction of Disease by Fr-MCF Virus 
Incidence of 
Strain  Age  Virus  disease  Latency 
%  d 
NIH Swiss  6 wk  Fr-MCF  0(0/8)  -- 
NIH Swiss  6 wk  F-MuLV  13(2/16)  95-138 
NIH Swiss  6 wk  F-MuLV/Fr-MGF  60(9/15)  52-114 
DBA/2  6 wk  F-MuLV  0(0/6)  -- 
DBA/2  6 wk  F-MuLV/Fr-MGF  0(0/7)  -- 
NIH Swiss  Newborn  Fr-MCF  0(0/8)  -- 
NIH Swiss  Newborn  Amph 4070  0(0/13)  -- 
NIH Swiss  Newborn  Amph/Fr-MCF  27(3/11)  52-100 
DBA/2  Newborn  Amph 4070  0(0/11)  -- 
DBA/2  Newborn  Amph/Fr-MCF  0(0/13)  -- 
Mice were injected with the designated virus and killed at  intervals between 2 and 6 mo 
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the  availability  of a  specific probe  for MCF  gp70.  MCF  gp70 can  be distinguished 
from  F-MuLV  gp70  by  the  size  of its  precursor  (80,000  mol  wt  as  compared  with 
85,000 mol wt  for the F-MuLV precursor)  and by its ability to be precipitated  with 
goat  anti-MCF  gp70  serum  that  has  been  made  MCF  specific  by absorption  with 
ecotropic  F-MuLV.  As shown  in  Fig.  1A,  this  serum  precipitates  Fr-MCF  gPr80  env 
but fails to precipitate  the gPr85  env of F-MuLV. 
To look for infectious viruses, cell-free spleen  homogenates from various F-MuLV- 
infected  resistant  and  susceptible  strains  of  mice  were  passaged  onto  NIH  3T3 
fibroblasts and the cells were pulse labeled and immune precipitated  with the MCF- 
gp70-specific antiserum. As shown in Fig.  1, NIH 3T3 fibroblasts infected with spleen 
homogenates from susceptible  NIH Swiss and BALB/c mice express an MCF-specific 
gp70 precursor (lanes B2 and C2), whereas no MCF-specific proteins could be detected 
in the NIH 3T3  fibroblasts  infected with spleen homogenates from resistant  DBA/2 
and C57BL/6 mice (lanes D2 and E2), indicating that MCF viruses are replicating in 
the spleens of susceptible  mice but not in the spleens of resistant  mice after infection 
with F-MuLV. Ecotropic gp70 precursors could be detected in the NIH 3T3 fibroblasts 
infected  with  spleen  homogenates from all  four strains  (lanes  B1, C1,  D1,  and  El), 
which is consistent  with  earlier  data indicating  that  F-MuLV is  able  to replicate  in 
both susceptible  and resistant  strains of mice. 
To  determine  whether  the  expression  of MCF  gp70  is  directly  correlated  with 
disease, NIH 3T3 fibroblasts infected with spleen homogenates from other F-MuLV- 
infected susceptible  and resistant  strains  were also analyzed for viral  protein expres- 
sion, and the results are summarized in Table IV. MCF gPr80  env could be detected in 
NIH  3T3  cells  infected  with  spleen  homogenates  from  all  of the  susceptible  mice 
tested  but  not from the resistant  mice.  MCF envelope proteins  could be detected  in 
NIH 3T3 cells infected with spleen  homogenates prepared  from disease-free AL and 
Fro.  l.  Immune  precipitates of NIH 3T3 cells infected with spleen homogenates from various 
strains of mice infected with F-MuLV. Cell-free spleen homogenates were prepared from  NIH Swiss 
(panel B), BALB/c (panel C), DBA/2  (panel D), and C57BL/6 (panel E) mice and passaged on 
NIH 3T3 cells. Cells were then pulse labeled with [3SS]methionine and immune precipitated with 
goat anti-Rauscher  MuLV gp70 serum (lanes 1), goat anti-Moloney-MCF gp70 serum absorbed 
with F-MuLV (lanes 2), goat anti-Rauscher MuLV p12 serum (lanes 3), and normal goat serum 
(lanes 4).  Panel A shows pulse-labeled NIH 3T3 cells infected with F-Mul.V  (c~, the left) or Fr- 
MCF  (on the right) that have been immune precipitated  w~'_  t'. soar anti-Rauscher  MuLV gp70 
serum (lanes 1), goat anti-Moloney MCF gp70 serum absorbed with F-MuLV (lanes 2), and normal 
goat serum (lanes 4). Immune precipitates were then electrophoresed on 7% SDS-PAGE gels and 
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TAnLE  IV 
Infectious MuL V in Cell-free Spleen Homogenates  from F-MuL V-infected 
Mice 
Mice infected with F-MuLV 
Viral proteins expressed  in 
NIH cells infected with spleen 
homogenates from infected 
mice* 
MCF-like  Strain  Disease  F-MuLV gp70  gp70:~ 
NIH Swiss  +  +  + 
BALB/c  +  +  + 
C3H/HeN  +  +  + 
AL/N  + or -  +  + 
NZW  + or -  +  + 
DBA/2  -  +  - 
C57BL/6  -  +  - 
C57BL/10  -  +  - 
CBA  -  +  - 
C57L  -  +  - 
NFS ×  DBA/2  -  +  - 
NFS x  C57BL/6  -  +  - 
BALB/c x  DBA/2  -  +  - 
* Mice  were  injected  as  newborns  with  F-MuLV  and  killed  at  1-2  mo 
postinfection.  Spleen homogenates were passaged  onto NIH 3T3 cells and 
protein expression  was determined by pulse labeling, immune precipitation, 
and SDS-PAGE, as described in Materials and Methods. Criteria for deter- 
mining disease are as described in Table I. 
~: The level of infectious MCF virus in the spleen homogenates from susceptible 
strains  of mice is apparently very low, as indicated by the need to passage 
the infected cells three to four times before virus could be detected as well as 
by direct assays on S+L- cat cells (R. Bassin, personal  communication). 
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NZW  mice,  suggesting  that  these  mice,  like  40%  of their  littermates,  might  have 
developed  disease  if killed  at  a  later  date.  These  results  are  consistent  with  MCF 
viruses playing a  role in the erythroproliferative  disease induced by F-MuLV. 
Analysis  of Cells from  Uninfected Mice for  Viral Protein Expression.  Although  the  data 
suggest that Fr-MCF  virus plays a  role in F-MuLV-induced  erythroleukemia,  it is not 
clear why certain  strains  of mice are  resistant  to  disease.  Immune  response  genes  do 
not  appear  to  be  responsible  for  resistance  because  no  differences  were  found  in 
antibody  levels to F-MuLV  or Fr-MCF  gp70  in the serum of DBA/2  and  NIH  Swiss 
mice  (unpublished  data).  Because  it  was  shown  that  MCF  viruses  replicate  only  in 
mice that  are susceptible to F-MuLV-induced  disease, we were interested in knowing 
whether  tissues  from  uninfected  susceptible  mice  but  not  resistant  mice  may  be 
expressing endogenous  MCF  viruses. When  cell-free bone marrow  or spleen homoge- 
nates from uninfected NIH  Swiss, BALB/c,  DBA/2,  or C57BL/6  mice were passaged 
onto NIH  3T3 cells, neither virus replication nor expression of MCF  envelope proteins 
could  be  detected  (data  not  shown).  Tissues  from  the  various  uninfected  mice were 
then  directly  examined  for  the  expression  of MCF  gPr80 env by  pulse  labeling  and 
immune  precipitation with specific sera. As shown in Fig. 2A, bone marrow cells from 
uninfected  NIH  Swiss  (panel  4)  and  BALB/c  (panel  5)  did  not  express  any  MCF- 
specific envelope proteins.  In contrast,  bone marrow  cells from DBA/2  (panel  1)  and 
C57BL/6  (panel  2)  express  an 80,000  mol wt  protein  that  is specifically precipitated 914  FRIEND MURINE  LEUKEMIA VIRUS-INDUCED  LEUKEMIA 
Fz~.  2.  Immune precipitates of bone marrow cell extracts from various strains of uninfected mice. 
(A) Bone marrow cells were removed from the femurs of uninfected  DBA/2 (panel  1), C57BL/6 
(panel 2), BALB/c ×  DBA/2 F1 hybrid (panel 3), NIH Swiss (panel 4), and BALB/c (panel 5) 
mice, pulse labeled with [~S]methionine, and immune precipitated  with goat anti-Rauscher MuLV 
gp70 serum (lanes a), goat anti-Moloney MCF gp70 serum absorbed with F-MuLV (lanes b), and 
normal goat serum (lanes c). Precipitates were then electrophoresed on 5-15% gradient SDS-PAGE 
gels and autoradiographed. (B) 3T3 embryo cell lines from DBA/2 (panel  1), C57BL/6  (panel 2), 
NIH Swiss (panel  3), and BALB/c (panel 4) mice were pulse labeled with  [~S]methionlne  and 
immune  precipitated with goat  anti-Rauscher MuLV gp70 serum  (lanes a),  goat  anti-Moloney 
MCF gp70 serum absorbed with F-MuLV (lanes b), and normal goat serum (lanes c). Precipitates 
were then electrophoresed on 7% SDS-PAGE gels and were autoradiographed. 
with  anti-MCF gp70  serum.  Bone marrow  cells from  BALB/c  X  DBA/2  Fa hybrid 
mice (panel 3)  also express an MCF  gPr80  env, indicating that the gene encoding this 
protein  is  dominant  or  that  the  expression  of this  protein  is  under  control  of a 
dominant  gene.  Because  MCF  viruses  are  envelope  gene  recombinants  between 
ecotropic and  xenotropic  viruses,  it  is likely that  the  MCF  gp70-specific antiserum 
used in this study would react with the envelope proteins encoded by the xenotropic 
progenitors  of MCF  viruses.  Therefore,  we  will  refer  to  the  endogenous  proteins 
detected by this antiserum as MCF/xenotropic virus-related envelope proteins. 
MCF/xenotropic  virus-related envelope proteins are present  not only in the cyto- 
plasm but  can  also be detected on  the surface of uninfected  DBA/2  and  C57BL/6 
bone  marrow  and  spleen  cells  as  determined  by  iodination  in  the  presence  of 
lactoperoxidase (data not shown).  Embryo fibroblast 3T3 lines derived from DBA/2 
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panels  1 and 2), whereas embryo fibroblasts derived from NIH Swiss and BALB/c 
mice do not (panels 3 and 4), which indicates that this protein is expressed in tissues 
outside of the hematopoietic system. The endogenous MCF/xenotropic virus-related 
gPrS0  env in DBA/2 fibroblasts is glycosylated and in pulse-chase experiments it can 
be chased into gp65 and pl5(E). In contrast to the expression of envelope proteins, no 
gag proteins were expressed in the DBA/2 fibroblast line (data not shown). 
The data,  therefore, show that  mice that  are resistant  to disease  induced by F- 
MuLV  endogenously express MCF/xenotropic virus-related envelope proteins that 
may somehow prevent F-MuLV or its MCF intermediate from inducing disease. 
Discussion 
The data reported here indicate that  MCF viruses play a  role in the erythropro- 
liferative disease  induced by F-MuLV.  This idea is supported  by the observations 
that expression of MCF viruses in mouse spleens can be correlated with erythroleu- 
kemia induced by F-MuLV, by the fact that Fr-MCF viruses injected as appropriate 
pseudotypes can cause a  similar  disease,  and  by the observation that  resistance to 
disease induced either by F-MuLV or Fr-MCF virus is correlated with the expression 
of endogenous  MCF/xenotropic  virus-related  envelope  proteins  that  may  block 
incoming MCF viruses by a mechanism analogous to viral interference. 
Although  Fr-MCF  virus  injected alone  into  susceptible  strains  of mice was  not 
pathogenic,  the virus was  shown  to be capable of inducing an erythroproliferative 
disease when injected as an F-MuLV or amphotropic virus pseudotype. This has been 
a  typical observation  for MCF  viruses.  Cloyd et  al.  (8)  observed that  AKR  MCF 
viruses were not pathogenic in NIH Swiss mice unless those mice carried one of the 
Akv virus-inducing loci and were thus expressing high levels of ecotropic MuLV. Vogt 
(9) noted that the infectivity of Moloney MCF in vitro was increased under conditions 
where  Moloney  MCF  pseudotypes  were  formed.  Van  Griensven  and  Vogt  (10) 
observed that Rauscher MCF virus effectively induced foci on the spleens of infected 
mice  only  after  the  formation  of pseudotypes  with  ecotropic  Rauscher  MuLV. 
Pseudotypes may facilitate the initial infection of target tissues with MCF viruses by 
packaging  the  MCF  viral  genomes  in  envelopes that  are  resistant  to  neutralizing 
factors present  in  normal  mouse serum.  These factors could include oncornavirus- 
inactivating factor (31-34), shown by Haas and Patch (35) to inactivate MCF viruses 
recovered from x-ray-induced lymphomas of C57BL/6 mice, or antibodies specific for 
determinants on MCF viral envelope proteins. Once within the target tissues, MCF 
viruses could then replicate and spread using their own envelopes. Alternatively, the 
viruses used to form pseudotypes could play another role in leukemogenesis in addition 
to providing a different envelope for the MCF genome, such as allowing for increased 
proliferation of target cells for MCF  viruses.  However, studies  by Haas  and  Patch 
(35)  have indicated that phenotypically mixed pseudotype virions were required for 
increasing the leukemogenicity of MCF viruses and could not be replaced by a simple 
mixture of ecotropic and MCF viruses. Whatever the mechanism, the formation of 
pseudotypes  with  ecotropic  viruses  may  be  an  important  step  in  leukemogenesis 
associated with MCF viruses. 
Although  F-MuLV  and  Fr-MCF  viruses are associated with erythroleukemia in 
certain strains  of mice, other strains  are  resistant  to the effects of these viruses.  A 
variety of mechanisms  may be responsible for the  failure of an  animal  to develop 916  FRIEND MURINE  LEUKEMIA VIRUS-INDUCED LEUKEMIA 
disease after injection of a particular virus. First, the input virus may not replicate in 
the mouse. The Fv-1 gene (27, 28)  as well as other genes (36-38) have been shown to 
control the replication of ecotropic viruses in certain strains of mice. Second, the input 
virus may not have enough  available target cells in resistant  strains of mice. It has 
been suggested that the Fv-2 gene, which controls susceptibility to disease induced by 
the spleen  focus-forming virus, may operate through  such  a  mechanism  (39).  Mice 
can also be resistant because of an effective immune response against either the input 
virus or the  virus-infected  target  cells.  Such  H-2-1inked  immune response  genes  as 
Rfv-1  and  Rfv-2  (40-42)  as  well  as  the  non-H-2-1inked  Rfv-3  (43)  are  thought  to 
operate through  such a  mechanism.  Additional  mechanisms for resistance to virus- 
induced  disease can be invoked if the input virus does not act directly but generates 
a second virus that is responsible for disease. In this case, the second virus may either 
not be generated in the resistant mouse or it may fail to replicate there either because 
of an effective immune response against it or because of viral interference. 
Our data indicate that the resistance of certain strains of mice to disease induced 
by F-MuLV cannot  be explained  by expression of Fv-1,  Fv-2,  or Rfv-like genes in 
these mice. Any proposed mechanism must take into account the following observa- 
tions: (a) resistance to F-MuLV disease is dominant; (b) resistance to F-MuLV disease 
is correlated with the failure to generate or replicate Fr-MCF  viruses; and  (c)  mice 
resistant  to F-MuLV disease are also resistant  to disease induced  by Fr-MCF pseu- 
dotypes. A  mechanism that would best incorporate these observations would be one 
in which resistant strains express a  factor that would block either the generation or 
the  replication  of Fr-MCF  viruses.  The  finding  that  uninfected  resistant  strains  of 
mice express endogenous MCF/xenotropic virus-like envelope proteins is compatible 
with such a  mechanism. The generation of MCF viruses after infection of mice with 
ecotropic virus is probably occurring at a low frequency. Thus, spread and replication 
of MCF  viruses  in  the  organs  in  which  they were  generated  would  be crucial  for 
generating  a  pathogenic  titer  of virus.  If the  endogenous  envelope  glycoproteins 
expressed in resistant strains of mice can block the receptors for the generated MCF 
viruses, their spread and replication would be prevented and a sufficient titer of virus 
to induce disease would never be achieved. Resistance would be dominant. The fact 
that endogenous MCF/xenotropic virus-related envelope proteins are not detected in 
susceptible strains of mice is consistent with this hypothesis.  Although  it is possible 
that  MCF  viruses  are  never  generated  in  resistant  strains  of mice,  the  fact  that 
pathogenic pseudotypes of Fr-MCF virus do not replicate or induce disease in strains 
resistant to F-MuLV disease is consistent with resistance being mediated through viral 
interference.  This idea is supported by recent  in  vitro studies  on  the replication  of 
MCF  viruses in  DBA/2  fibroblasts  (R.  Bassin,  manuscript  in  preparation).  Such  a 
mechanism would  be similar to that  proposed by Stockert  et  al.  (44),  who showed 
that inhibition of MCF virus-mediated AKR leukemogenesis could be inhibited by a 
nonleukemogenic  MCF  virus  and  suggested  viral  interference  as  the  most  likely 
mechanism. Although we have not been able to induce or transmit a  virus encoding 
endogenous  MCF/xenotropic  virus-like  envelope  proteins  from  DBA/2  or  other 
resistant strains, the expression of viral gp70 alone in these mice may be adequate for 
causing  viral  interference.  In  support  of this  is  a  recent  observation  by  A.  Rein 
(unpublished  data)  that  cells  infected  with  a  defective AKR  virus expressing only 
envelope proteins still exhibit type-specific viral interference. SANDRA RUSCETTI,  LEONORA  DAVIS, JOHN  FEILD, AND ALLEN OLIFF  917 
The  expression  of an  endogenous  MCF/xenotropic  virus-related  gp70  does  not 
appear to block disease induced by the SFFV, a virus that codes for an envelope gene 
product, gp52, that cross-reacts with the gp70 of Fr-MCF virus (25, 45). NIH Swiss as 
well  as  DBA/2  mice  are  susceptible  to  SFFV-induced  erythroleukemia.  However, 
gp52 does not appear in virus particles after rescue with F-MuLV and thus does not 
contribute to binding of virions to receptors on the cell surface. Thus, a  resistance 
mechanism based on viral interference would not be expected to affect susceptibility 
to SFFV. 
We are in the process of carrying out more detailed genetic studies to determine the 
number  and  location  of genes  involved  in  resistance  to  F-MuLV  disease  and  to 
determine the mechanism by which the expression of endogenous MCF/xenotropic 
virus-related envelope glycoproteins can play a role in this resistance. 
Summary 
In these studies, we have shown data that are consistent with the hypothesis that 
mink cell focus-inducing viruses (MCF)  play an important role in the generation of 
an erythroproliferative disease developing after injection of certain strains of newborn 
mice  with  ecotropic  Friend  murine  leukemia  virus  (F-MuLV).  Resistance  to  this 
disease  is correlated with  the endogenous expression of an  MCF/xenotropic virus- 
gpT0-related protein that may interfere with the replication or spread of MCF viruses. 
These ideas are supported by the following observations:  (a)  after infection with F- 
MuLV, only 6/13 strains of mice developed disease, and studies with crosses between 
susceptible and resistant strains indicated that resistance was dominant. Although F- 
MuLV was  shown to replicate equally well in all strains  tested, viruses coding for 
MCF-specific viral envelope proteins could be detected only in the spleens of mice 
from strains that were susceptible to F-MuLV-induced disease and not in the spleens 
of mice from strains  that  were resistant  to  F-MuLV-induced  disease;  (b)  a  Friend 
MCF (Fr-MCF) virus isolated from the spleen of an F-MuLV-infected mouse from a 
susceptible strain induced the same erythroproliferative disease when injected as an 
appropriate pseudotype into mice from susceptible but not resistant strains of mice; 
and  (c)  resistant  but  not  susceptible  strains  of mice  endogenously express  MCF/ 
xenotropic virus-related envelope glycoproteins that may be responsible for resistance 
by blocking receptors for MCF viruses. These results not only indicate that Fr-MCF 
virus is a crucial intermediate in the induction of disease by F-MuLV, but also suggest 
that a  novel gene, either an MCF/xenotropic virus-related envelope gene or a  gene 
controlling its expression, is responsible for resistance to erythroleukemia induced by 
F-MuLV. 
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